EN
Home/United States/Answers/Ozempic for weight loss
USUnited States Medicines

Is Ozempic for weight loss or diabetes?

GLP Guidebook teamUpdated Oct 18, 202610 sourcesWritten from published sources
What we checked10 sources, each one opened and linked to the sentence it supportsLast checked Oct 18, 2026 · Next review due Oct 18, 2027 · How we write
The short answer

Ozempic is a brand of semaglutide that the FDA approved for type 2 diabetes, not for weight loss. The same medicine is approved for weight as Wegovy, at higher doses: 2.4 mg a week, or 7.2 mg for some adults. Using Ozempic for weight is off-label, and Medicare can't cover it for that.

Before you go further

What is Ozempic FDA-approved for?

Ozempic’s US label covers adults with type 2 diabetes: lowering blood sugar, and lowering the risk of heart and kidney problems.1

The medicine inside is semaglutide. Ozempic and Wegovy are two brands of it, both made by Novo Nordisk, in the way Tylenol is a brand of acetaminophen. The FDA approved them for different uses and different top doses:1,2

Brand (medicine)FDA-approved forTop weekly dose
Wegovy (semaglutide)Weight, heart protection, fatty liver with scarring (MASH)2.4 mg; 7.2 mg for some adults
Ozempic (semaglutide)Type 2 diabetes, heart and kidney protection in diabetes2 mg

From the US labels.1,2 The brand tree is in Guide 2.

Why do people call Ozempic a weight-loss drug?

Ozempic came out four years before Wegovy, and its diabetes trials already showed weight loss.

  • It was approved first. Ozempic was approved for diabetes in 2017. Wegovy followed in June 2021, the first new weight drug since 2014.3
  • The diabetes trials showed weight loss. In a 30-week Ozempic trial in 388 adults with type 2 diabetes, people on 1 mg lost about 10 lb (4.7 kg) on average, against about 3 lb (1.2 kg) on a placebo (dummy injection).1
  • Demand outran supply. The FDA says semaglutide injections were in shortage from 2022 “due to increased demand”. It declared the shortage over on February 21, 2025.5

What does “off-label” mean?

Off-label means using an FDA-approved medicine for something its label doesn’t cover, such as Ozempic for weight loss.4

The FDA’s own words: “Unapproved use of an approved drug is often called ‘off-label’ use.” It adds that “healthcare providers generally may prescribe the drug for an unapproved use when they judge that it is medically appropriate for their patient.”4 That makes it the prescriber’s call, not an FDA approval.

What does that mean for you?

Using Ozempic for weight changes who pays, how high the dose can go, and nothing about the medicine’s risks.

  • Cover. By law, Medicare can’t cover medicines used only for weight loss; Part D plans cover GLP‑1s for approved uses such as type 2 diabetes.6 Medicare’s temporary GLP‑1 Bridge covers, most searched first, Foundayo, the Zepbound KwikPen and Wegovy for weight, but not Ozempic.6 Employer plans vary: 16% of firms with 200 to 999 workers and 43% with 5,000 or more cover GLP‑1s for weight.7 See Insurance, and Prices for self-pay.
  • Dose. Ozempic stops at 2 mg a week.1 Wegovy goes to 2.4 mg, and up to 7.2 mg for adults who have managed 2.4 mg for at least 4 weeks.2 In the STEP 2 trial in people with type 2 diabetes, weight fell 9.6% on 2.4 mg and 7.0% on 1 mg, an Ozempic dose, against 3.4% on a dummy injection, over 68 weeks.8 For someone starting at 220 lb (100 kg), that’s about 21 lb against 15 lb. These are averages; Ozempic vs Wegovy has the detail.
  • Supply. The shortage is over, the FDA says.5 Compounded copies are a separate question: Is compounded semaglutide the same as Ozempic?
  • Safety. It’s the same medicine, so both labels carry the same thyroid tumor warning.1,2 The Wegovy label says not to use it with other semaglutide products, Ozempic included.2
RisksThe risks, in brief
  • Stomach effects are common. In Ozempic’s diabetes trials, 20 in 100 people on 1 mg had nausea, against 6 in 100 on a dummy injection.1
  • Thyroid warning. Not for anyone with a personal or family history of medullary thyroid carcinoma (a rare thyroid cancer) or MEN 2 (an inherited condition that causes gland tumors).1
  • Pregnancy. The Wegovy label says to stop at least 2 months before a planned pregnancy.2
Full detail in Guide 5: Side effects and risks →

Is Mounjaro the same story?

Yes. In the US, Mounjaro (tirzepatide) is approved for type 2 diabetes only, and Zepbound is the same tirzepatide approved for weight.9,10

Coverage follows the same split. See Mounjaro vs Zepbound: what’s the difference?

What does a doctor weigh?

A prescriber starts from what you’re treating, then checks the label and your history.

  • Diabetes or not. With type 2 diabetes, Ozempic is an approved use.1 Without it, Wegovy and Zepbound are the semaglutide and tirzepatide brands approved for weight.2,10
  • Your BMI and health. Wegovy’s weight trials enrolled adults with a BMI of 30 or more, or 27 or more with a weight-related condition.2 See What BMI do you need for Wegovy?
  • Your history. Thyroid cancer in the family, pancreatitis, pregnancy plans, and diabetes medicines such as insulin, which raise the risk of low blood sugar.1
  • Cover. Whether your plan pays for that use.6,7

Read the full picture

Related questions

What BMI do you need for Wegovy? Does Medicare cover Zepbound or Wegovy? Mounjaro vs Zepbound: what’s the difference? Is compounded semaglutide the same as Ozempic? Can I get Ozempic online legally?
Did this answer your question?

Sources

  1. Novo Nordisk. Ozempic (semaglutide) injection, US prescribing information and Medication Guide, revised 05/2026 (sections 1, 2.2, 6.1 and 14; boxed warning). US label. novo-pi.com (PDF)
  2. Novo Nordisk. Wegovy (semaglutide) injection and tablets, US prescribing information, revised 06/2026 (sections 1, 2.2, 6.1, 8.3 and 14; limitations of use). US label. novo-pi.com (PDF)
  3. FDA. FDA approves new drug treatment for chronic weight management, first since 2014. Press release, Jun 4, 2021 ("Semaglutide 1 mg injection (Ozempic) was first approved as a treatment for type 2 diabetes in 2017"). fda.gov (archived copy)
  4. FDA. Understanding unapproved use of approved drugs "off label". Content current as of Feb 5, 2018. fda.gov
  5. FDA. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (update of Feb 21, 2025: semaglutide shortage resolved). Content current as of Apr 1, 2026. fda.gov
  6. KFF. What to know about the BALANCE Model for GLP-1s in Medicare and Medicaid and the Medicare GLP-1 Bridge. Updated May 11, 2026. kff.org
  7. KFF. 2025 Employer Health Benefits Survey, section on GLP-1 coverage for weight loss. Oct 22, 2025. kff.org
  8. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet 2021;397:971-984. Funded by Novo Nordisk. doi:10.1016/S0140-6736(21)00213-0 · PMID 33667417
  9. Eli Lilly. Mounjaro (tirzepatide) US prescribing information, revised 08/2026, section 1. US label. uspl.lilly.com
  10. Eli Lilly. Zepbound (tirzepatide) US prescribing information, revised 08/2026, section 1. US label. uspl.lilly.com

Last checked Oct 18, 2026 · Next review due Oct 18, 2027 · Report an error

How this answer was made. Written by the GLP Guidebook team from the sources above, all checked on Oct 18, 2026. It’s general information, not medical advice, and not a reason to use a medicine off-label. Talk to a doctor, pharmacist or other licensed prescriber before starting, stopping or changing any medicine. In an emergency, call 911. How we write